Pharmacokinetics, Safety and Tolerability of Zongertinib Following Oral Administration in Male and Female Participants of Non-childbearing Potential With Different Degrees of Hepatic Impairment (Child-Pugh Classification A and B) Compared With Matched Male and Female Participants of Non-childbearing Potential With Normal Hepatic Function (an Open-label, Non-randomised, Single-dose, Parallel, Individual-matched Design Trial)

This study is open to adults between 18 and 80 years of age. People with a body mass index (BMI) between 18 and 42 kg/m^2 can take part. Women can only participate if they cannot get pregnant. This study includes people with mild liver problems, people with moderate liver problems, and people without liver problems as a matching control. The purpose of this study is to find out how mild and moderate liver problems affect how the body handles a medicine called zongertinib.
Participants take zongertinib once as tablets. Participants with liver problems are treated in a step-by-step approach with a few days in between for the doctors to review the data and make sure the participants can tolerate the treatment. Participants may continue their regular treatment for their liver problems during the study.
Participants are in the study for about 5 weeks. During this time, they visit the study site 4 times. This also includes an overnight stay for 6 nights. During study visits, the doctors regularly check participants' health and take note of any unwanted effects. To assess the study endpoints, the study staff regularly takes blood samples.

开始日期2025-01-15

申办/合作机构

Boehringer Ingelheim GmbH

CTR20242277

/ Recruiting临床1/2期

Beamion BCGC-1：一项评价口服zongertinib（BI 1810631）联合德曲妥珠单抗（T-DXd）静脉给药或联合恩美曲妥珠单抗（T-DM1）静脉给药用于治疗晚期HER2+转移性乳腺癌（mBC）和转移性胃癌、食管胃结合部癌或食管腺癌（mGEAC）患者的Ib期剂量递增和II期剂量优化、随机、开放性、多中心临床研究

本研究的目的是确定zongertinib与德曲妥珠单抗或恩美曲妥珠单抗联合治疗时对已扩散的不同类型HER2+癌症患者的最佳耐受剂量。另一个目的是检查zongertinib与T-DXd或T-DM1联合使用是否可以使肿瘤缩小。Zongertinib 抑制 HER2。HER2 导致癌细胞生长。

开始日期2024-10-25

申办/合作机构

勃林格殷格翰（中国）投资有限公司

[+3]

NCT06581432

/ Recruiting临床2期

Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours

This is a study for people with advanced cancer for whom previous treatment was not successful or no treatment exists. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2.
Participants are put into 10 groups based on the type of advanced cancer and the type of HER2 alterations they have. All participants take one dose of zongertinib. Participants can continue the treatment as long as they benefit from it and can tolerate it.
Participants visit the study site regularly. During many of the visits, the doctors check the size of the tumour and whether it has spread to other parts of the body. During all the visits, the doctors check participants' health and take note of any unwanted effects.

开始日期2024-10-11

申办/合作机构

C.H. Boehringer Sohn AG & Co. KG

100 项与宗格替尼相关的临床结果

登录后查看更多信息

100 项与宗格替尼相关的转化医学

登录后查看更多信息

100 项与宗格替尼相关的专利（医药）

登录后查看更多信息

项与宗格替尼相关的文献（医药）

2025-02-01·Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

The effect of carbamazepine, a strong CYP3A inducer, on the pharmacokinetics of zongertinib in healthy male volunteers

Article

作者: Minich, David ; Grempler, Rolf ; Mahmoudi, Mazyar ; Sadrolhefazi, Behbood ; Müller, Fabian ; Esmaeili, Habib ; Seitz, Friedeborg ; Roessner, Philipp M. ; Tian, Xiaofan ; Gan, Guanfa ; Wind, Sven ; Chan, Tom S.

AbstractIntroductionZongertinib (BI 1810631) is a potent, selective, and epidermal growth factor receptor (EGFR) wild‐type sparing human epidermal growth factor receptor 2 (HER2) inhibitor. Based on in vitro data, the oxidative hepatic metabolism of zongertinib is principally driven by cytochrome P450 (CYP) 3A4/5. Therefore, zongertinib may be affected by strong CYP3A inducers, like carbamazepine.ObjectiveThis study aimed to investigate the effect of multiple oral doses of carbamazepine on the pharmacokinetics of a single oral dose of zongertinib in healthy male subjects.MethodsThis open‐label, two‐period, fixed‐sequence clinical drug–drug interaction study examined the pharmacokinetics of a single 60‐mg oral dose of zongertinib in the absence or presence of multiple oral doses of carbamazepine. The extent of drug–drug interaction was estimated using the adjusted geometric mean ratios (and 90% confidence intervals [CIs]) for the test treatment (zongertinib in the presence of carbamazepine) versus the reference treatment (zongertinib alone) for areas under the plasma concentration–time curve from time 0 to infinity and to the last quantifiable time point (AUC0–∞, AUC0–tz) and maximum measured plasma concentration (Cmax).ResultsSixteen subjects (all Caucasian males) received zongertinib alone in Study Period 1, and 15 of them received both zongertinib and carbamazepine in Study Period 2. Upon co‐administration with carbamazepine in Study Period 2, AUC0–∞ and AUC0–tz of zongertinib were both reduced to 36.5% (90% CI: 32.0%–41.6% for AUC0–∞ and 31.9%–41.7% for AUC0–tz). The Cmax of zongertinib was reduced to 56.4% (90% CI: 45.1%–70.6%).ConclusionZongertinib exposure was reduced by 63.5% when coadministered with the strong CYP3A inducer, carbamazepine.

2025-01-13·Cancer Discovery

Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Article

作者: Vainorius, Gintautas ; Popow, Johannes ; Ikegami, Masachika ; Woelflingseder, Lydia ; Spreitzer, Fiona ; Kraut, Norbert ; Kohsaka, Shinji ; Augsten, Martin ; Obenauf, Anna C. ; Baum, Anke ; Pearson, Mark A. ; Tilandyová, Sylvia ; Chylinski, Krzysztof ; Bruining, Annemarie ; Solca, Flavio ; Heymach, John V. ; Wilding, Birgit ; Neumüller, Ralph A. ; Scharn, Dirk ; Opdam, Frans L. ; Gerlach, Daniel ; Shirai, Yukina ; Yamamoto, Noboru ; Gibson, Neil ; Waizenegger, Irene C. ; Kondo, Shunsuke

AbstractMutations in ERBB2 (encoding HER2) occur in 2% to 4% of non–small cell lung cancer (NSCLC) and confer poor prognosis. ERBB-targeting tyrosine kinase inhibitors, approved for treating other HER2-dependent cancers, are ineffective in HER2-mutant NSCLC due to dose-limiting toxicities or suboptimal potency. We report the discovery of zongertinib (BI 1810631), a covalent HER2 inhibitor. Zongertinib potently and selectively blocks HER2, while sparing EGFR, and inhibits the growth of cells dependent on HER2 oncogenic driver events, including HER2-dependent human cancer cells resistant to trastuzumab deruxtecan. Zongertinib displays potent antitumor activity in HER2-dependent human NSCLC xenograft models and enhances the activities of antibody–drug conjugates and KRASG12C inhibitors without causing obvious toxicities. The preclinical efficacy of zongertinib translates in objective responses in patients with HER2-dependent tumors, including cholangiocarcinoma (SDC4–NRG1 fusion) and breast cancer (V777L HER2 mutation), thus supporting the ongoing clinical development of zongertinib.Significance: HER2-mutant NSCLC poses a challenge in the clinic due to limited options for targeted therapies. Pan-ERBB blockers are limited by wild-type EGFR–mediated toxicity. Zongertinib is a highly potent and wild-type EGFR–sparing HER2 inhibitor that is active in HER2-driven tumors in the preclinical and clinical settings.

2024-01-01·Cancer Treatment and Research Communications

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report

Article

作者: Illini, Oliver ; Fabikan, Hannah ; Valipour, Arschang ; Weinlinger, Christoph ; Lang-Stöberl, Anna Sophie ; Hochmair, Maximilian J

INTRODUCTIONTreatment options for HER2-mutant patients with non-small cell lung cancer (NSCLC) are limited. New agents, including zongertinib, a HER2-selective tyrosine kinase inhibitor (TKI), are being investigated in clinical trials. However, published clinical data on the efficacy and safety of zongertinib are limited to data from a single phase I trial including only 36 patients with NSCLC.METHODSWe report real-world data on six consecutive patients with HER2-mutant NSCLC who received zongertinib through a named patient use program between December 2023 and June 2024. Radiological response evaluation and blood testing were routinely performed every two to three months, and adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.RESULTSAll patients were diagnosed with a metastatic adenocarcinoma, had previously progressed on at least one line of chemotherapy and had been previously treated with trastuzumab-deruxtecan (two had to stop treatment because of pneumonitis). Three patients (50%) presented with an Eastern Cooperative Oncology Group (ECOG) performance status of ≥2. A clinical and radiological benefit was achieved in all patients (complete response (1), partial response (4), and stable disease (1)). In one patient with brain metastases, a complete response was achieved. Treatment with zongertinib is ongoing in all patients. Adverse events were reported in one patient (elevated blood pressure (grade 1).CONCLUSIONZongertinib may be an effective and well-tolerated treatment option for HER2-mutant NSCLC patients even if they are heavily pretreated, have a reduced performance status or have a history of pneumonitis and brain metastases.

107

项与宗格替尼相关的新闻（医药）

2025-03-13

·癌度

免疫治疗误区，高龄患者使用PD-1抑制剂生存期降低近50%！

癌度医学临床招募资讯微信群（点击）免疫检查点抑制剂（PD-1或PD-L1抑制剂）彻底改变了非小细胞肺癌的治疗，免疫检查点抑制剂的治疗机制是松开被癌细胞抑制的免疫T细胞，一般来说用免疫治疗需要检测PD-L1表达水平，如果癌细胞的PD-L1表达大于50%则可以单独使用免疫治疗，不需要和化疗搭配使用。三期临床试验Keynote024给出了临床疗效数据，双药铂类化疗的中位无进展生存时间是5.5个月，而免疫治疗的帕博利珠单抗的中位无进展生存时间是7.7个月。两组患者的中位总生存时间分别是13.4个月和26.3个月，也就是如果PD-L1表达很高，单独使用免疫治疗的患者生存期比标准化疗更好。不过以上临床试验数据有个问题是排除了部分肿瘤患者，比如80岁的肿瘤患者是不能被纳入临床试验的，而肿瘤本身是一个老年疾病，那么80岁以上老人如果PD-L1也是高表达的情况，可以单独使用免疫治疗吗？疗效数据如何？今天癌度就给大家分享一个最新刊登的临床试验报道，希望这些内容对大家有所帮助，以便于在治疗过程做好相应的治疗决策。参考文献刊例示意图 1、肺癌一线治疗选择PD-1对80岁以上老人的疗效这是一项多中心、回顾性研究，包括2017年5月至2019年11月期间招募的所有非小细胞肺癌患者，这些患者的PD-L1表达大于50%，也就是属于PD-L1高表达的情况，这些患者确诊之后均使用了PD-1抑制剂帕博利珠单抗单药治疗，也就是没有搭配使用化疗。共计纳入了844名患者，其中73名患者年龄大于80岁，中位随访时间是45.7个月。 80岁以上老人单药PD-1抑制剂疗效降低如上面的图示，两条生存期曲线明显地拉开了。80岁以上患者的中位总生存时间是12个月，而小于80岁的患者单药PD-1的中位总生存时间是23.9个月。89岁以上老人的中位无进展生存时间是5个月，而小于80岁非小细胞肺癌使用单药PD-1的中位无进展生存时间是8.3个月。两组患者在客观治疗应答率方面没有显著差异。 2、面对问题，可能的解决办法对于年龄比较大的非小细胞肺癌患者，一般来说考虑年龄和体质都会尽量避免化疗，有的时候会通过检测PD-L1表达情况，但即便是PD-L1高表达似乎单药免疫治疗效果也是不理想。上面的临床试验可是有844人的数据，80岁以上老人的数量是73名，因此上面的生存期数据是具有一定代表性的。由于免疫治疗的机制是调动人体免疫系统攻击癌细胞，而高龄老人的免疫力可能是比较偏弱的，这种情况下将PD-1抑制剂搭配化疗是否增加疗效也不是很清楚，至少目前还没相关研究数据。当然对非小细胞肺腺癌患者来说，还有一把尚方宝剑就是靶向药，一定要明确患者的基因突变信息、免疫组化检测蛋白异常表达，看看能不能争取靶向药、抗体偶联药的使用，以更好地控制病情。相应的分子诊断检测结果大家可以关注并联系癌度咨询。参考文献： Lionel Falchero, et al., efficacy in octogenarians with NSCLCs expressing ≥50% PD-L1 (ESCKEYP GFPC 05-2018), Clinical Gwenaelle Legarff,Lung Cancer (2025). 往期推荐剑指癌王胰腺癌，癌症治疗疫苗让37%的高危患者术后3年无复发！ HER2系列之一，宗格替尼治疗HER2阳性实体瘤，30%患者肿瘤病灶大幅度缩小！ Claudin 18.2系列之一，多种实体肿瘤可受益于这个新靶点的抗癌药，这次点名双抗药QLS31905！ 90%的人不知道！春季免疫逆袭全靠这个“菌”队！

免疫疗法临床结果临床3期

2025-03-12

·癌度

剑指癌王胰腺癌，癌症治疗疫苗让37%的高危患者术后3年无复发！

癌度医学临床招募资讯微信群（点击）如果说什么类型的恶性肿瘤最为可怕，那么无疑是胰腺癌。胰腺癌的治疗是非常困难的，比较特别的组织结构导致药物难以渗入，PD-1抑制剂在很多类型的恶性肿瘤获得批准，但是PD-1抑制剂治疗胰腺癌是比较困难的。尽管胰腺癌比较难以早期发现，但是还是有一部分胰腺癌患者能在确诊的时候有手术机会，但是手术之后不代表永不复发，复发是胰腺癌患者术后的难解之题。今天癌度给大家分享的一篇研究是mRNA癌症疫苗，这个研究纳入了16名胰腺癌患者，他们在体检时发现了胰腺癌后参加了临床试验，根据患者肿瘤的基因突变信息设计了mRNA癌症疫苗，根据发布在国际著名学术期刊《自然》的研究结果，16名患者用了这款癌症疫苗之后，8名患者有强烈的免疫反应，其中6名患者在三年多之后没有癌症，而没有发生免疫反应的8名患者7名出现了病情复发。我们一起看看这个癌症疫苗的情况，以及给到我们什么样的信息。参考文献刊例示意图 1、癌症治疗疫苗对胰腺癌的疗效癌症疫苗面临的一个根本挑战是产生针对肿瘤抗原的长寿命功能性免疫T细胞，研究者发现了mRNA脂质体疫苗能解决胰腺导管腺癌的这一问题（促使产生足够的免疫T细胞）。这个一期临床试验招募的患者是早期胰腺癌病人，这些患者手术之后使用了PD-L1抑制剂阿替利珠单抗、改良的化疗方案和mRNA癌症疫苗。然后对患者进行了长达3.2年的长时间随访。 mRNA疫苗促进免疫T细胞的产生从上面的图示看出，没有接受疫苗诱导T细胞的无反应患者中位无复发时间是13.4个月，而使用了疫苗的患者中位无复发时间还没有达到（大于3.2年）。对于有免疫治疗诱导免疫细胞的患者，平均估计寿命是7.7年，每一个患者有86%的免疫T细胞在接种疫苗后3年还存在。当然不是每一个患者使用疫苗后都有好的效果，区别在于胰腺癌患者的脾脏是否在手术中被切除，因为脾脏在免疫功能中起着至关重要的作用。 2、更大规模的临床试验正在进行癌症治疗疫苗无疑是最近的研究热点，因为目前批准的免疫治疗药物很难满足需求，患者需要的是长期生存。癌症治疗疫苗可以诱导长时间存在患者体内的免疫T细胞，这无疑是让患者可以长期生存的关键。根据这一项报道，一项更大规模的临床试验正在进行，重点关注的是脾脏完整的早期胰腺癌患者。此外癌度也提醒大家注意肿瘤病灶的基因突变信息，如果说之前的研究是找靶向药为唯一目标，那么未来则是通过基因测序了解患者的癌细胞基因突变，为个性化癌症治疗疫苗做准备，不能等以后想用疫苗治疗了结果发现没有相应的基因突变数据和信息。关于基因检测和治疗相关问题欢迎大家加入癌度病友群交流咨询！参考文献： Zachary Sethna et al, RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer, Nature (2025). 往期推荐 HER2系列之一，宗格替尼治疗HER2阳性实体瘤，30%患者肿瘤病灶大幅度缩小！ Claudin 18.2系列之一，多种实体肿瘤可受益于这个新靶点的抗癌药，这次点名双抗药QLS31905！ KRAS系列之二：PCM-075联合化疗和贝伐单抗让76%肠癌KRAS突变患者病灶缩小，生存期翻倍！ ALK基因变异亚型、TP53共突变影响了患者靶向药的有效期、生存时间！

信使RNA疫苗临床结果免疫疗法临床1期

2025-03-11

·癌度

HER2系列之一，宗格替尼治疗HER2阳性实体瘤，30%患者肿瘤病灶大幅度缩小！

癌度医学临床招募资讯微信群（点击）人表皮生长因子受体2（HER2）是ERBB家族的一个基因，这个基因家族还有一个大名鼎鼎的爱捣乱的分子——EGFR基因。EGFR基因在非小细胞肺腺癌里非常高频地发生突变，50%的肺腺癌患者因为这个基因突变可以选择靶向药治疗。HER2基因在乳腺癌和胃癌里比较常见，HER2发生突变的形式包括HER2基因突变和HER2基因扩增、HER2蛋白高表达。其中HER基因突变和扩增可以使用基因测序技术来确定，HER2蛋白高表达则是通过免疫组化检测。 HER2突变的非小细胞肺癌占所有非小细胞肺癌的2%至5%，这类患者预后不良、脑转移率比较高，治疗难度大。迄今为止，针对HER2阳性的肺癌仅有一种靶向疗法（德曲妥珠单抗）。但是HER2阳性肺癌的治疗需求仍是未被满足。 1、HER2阳性肺癌的特点非小细胞肺癌的HER2突变大多数发生在特定的位置，其中20号外显子插入突变占主导，最常见的外显子20插入是A775_G776insYVMA，其他的突变形式也存在，但总体频率不是很高。尽管HER2基因20外显子插入突变对抗体偶联药如德曲妥珠单抗敏感，但是对口服靶向药是耐药的，比如阿法替尼、达克替尼等口服靶向药对这类突变无治疗效果。一些泛靶点的ERBB口服靶向药如吡咯替尼、泼奇替尼对HER2基因20外显子有效，但是也往往伴随相关毒性，比如腹泻和皮疹。这个主要的原因可能是因为是泛靶点，所以不良反应发生率也高。今天给大家介绍的宗格替尼是一种新型口服靶向药，可以选择性抑制HER2但不抑制EGFR，从而限制了相关毒性。下面就是关于宗格替尼的一个临床试验结果，这也是该药的首次人体、多中心的临床试验结果。本文参考文献刊例示意图 2、宗格替尼治疗HER2阳性肺癌疗效数据这是一个代号为Beamion LUNG-1的临床试验，评估每日两次使用宗格替尼（15至150毫克）或每日一次（60至360毫克）给药的效果和安全性。截止2024年5月23日，一共有105名患者接受了治疗，后面推荐的扩展剂量为每日一次120毫克和每日一次240毫克宗格替尼。宗格替尼治疗HER2阳性肺癌的治疗应答率如上面的图示，经过确认，所有剂量组30%的可评估疗效患者的肿瘤病灶缩小幅度超过了30%（治疗应答率），中位缓解持续时间为12.7个月。对于之前接受过HER2靶向治疗的肺癌患者有28%的患者病灶缩小超过30%，HER2基因的A775_G776insYVMA突变患者治疗应答率为38%，每日一次接受宗格替尼治疗非小细胞肺癌的中位无进展生存时间是17.2个月。 3、这款药的未来从上面的疗效数据看，宗格替尼的治疗效果是相当不错的，不管是初治还是经治HER2阳性肺癌都有患者产生治疗应答。上面的临床试验是一期临床试验，这个数据还不能支持这个药物获批，因此这款药会开展二期临床试验以探索好的剂量探索疗效数据，大家可以根据自己的基因检测报告来联系癌度申请入组，以争取获得免费使用这款口服靶向药的机会。癌度与吉因加启动的“基因检测人人可及”计划里，仅需要3000元就能检测36个基因，大家可以联系癌度或扫描上面的二维码咨询癌度医学顾问，了解基因检测的相关问题。参考文献： John V. Heymach, MD, PhD, et al., HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study, Journal of Clinical Oncology (2025). 往期推荐 Claudin 18.2系列之一，多种实体肿瘤可受益于这个新靶点的抗癌药，这次点名双抗药QLS31905！ KRAS系列之二：PCM-075联合化疗和贝伐单抗让76%肠癌KRAS突变患者病灶缩小，生存期翻倍！ ALK基因变异亚型、TP53共突变影响了患者靶向药的有效期、生存时间！话说肺癌新药，HER2抗体偶联药瑞康曲妥珠单抗刊登《柳叶刀》，73%患者病灶缩小超30%以上！

临床结果

100 项与宗格替尼相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HER2突变型非小细胞肺癌	申请上市	中国	Boehringer Ingelheim International GmbH	2025-01-15
食管腺癌	临床2期	意大利	Boehringer Ingelheim GmbH	2024-06-28
食管腺癌	临床2期	日本	Boehringer Ingelheim GmbH	2024-06-28
食管腺癌	临床2期	比利时	Boehringer Ingelheim GmbH	2024-06-28
食管腺癌	临床2期	美国	Boehringer Ingelheim GmbH	2024-06-28
HER2阳性食管腺癌	临床2期	日本	Boehringer Ingelheim International GmbH	2024-06-28
HER2阳性食管腺癌	临床2期	比利时	Boehringer Ingelheim International GmbH	2024-06-28
HER2阳性食管腺癌	临床2期	美国	Boehringer Ingelheim International GmbH	2024-06-28
HER2阳性食管腺癌	临床2期	意大利	Boehringer Ingelheim International GmbH	2024-06-28
HER2阳性食管腺癌	临床2期	西班牙	Boehringer Ingelheim International GmbH	2024-06-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04886804 (BEAMION LUNG-1, PRNewswire) 人工标引	临床1期	HER2突变型非小细胞肺癌	-	zongertinib (每日120毫克，单次服用)	(衊積築齋獵壓衊膚餘獵) = 築糧鹹齋選網窪齋膚願築遞顧膚範糧醖齋憲淵 (鬱築鬱夢衊艱艱淵願鏇 ) 更多	积极	2024-12-10
NCT04886804 (Beamion LUNG-1, ESMO_ASIA2024) 人工标引	临床1期	HER2阳性实体瘤	105	Zongertinib	(艱鹽憲襯鬱窪製簾簾範) = MTD was not reached for BID or QD schedules. 蓋壓願網簾鑰製廠膚鹹 (襯憲淵糧艱簾繭鏇繭鹽 ) 更多	积极	2024-12-07
				Zongertinib (Asian pts)
NCT04886804 (Beamion LUNG-1, WCLC2024) 人工标引	临床1期	HER2阳性实体瘤	83	Zongertinib BID	(選網範繭築製窪廠遞廠) = 膚齋築選鬱願鹹壓夢繭願衊齋糧網鹽範齋網鑰 (淵膚廠憲窪醖淵選衊顧 ) 更多	积极	2024-09-10
				Zongertinib QD	(淵醖觸艱範鏇夢襯鬱鏇) = 廠糧遞選鬱襯壓範糧壓艱鹽簾顧觸蓋糧製餘製 (構憲窪壓蓋鏇鹽艱壓夢 ) 更多
NCT04886804 (Beamion LUNG-1, ASCO2024) 人工标引	临床1期	HER2阳性实体瘤	61	Zongertinib 15/30/60/100/150 mg BID	(築蓋淵鹹獵製範壓製鑰) = 壓範鹽願鹽積糧繭願築鹹繭襯鑰觸簾築觸網蓋 (糧衊憲鏇艱製壓鬱餘鑰 ) 更多	积极	2024-05-24
				Zongertinib 60/120/180/240/300/360 mg QD	(築蓋淵鹹獵製範壓製鑰) = 鏇齋簾選廠醖遞積憲構鹹繭襯鑰觸簾築觸網蓋 (糧衊憲鏇艱製壓鬱餘鑰 ) 更多
NCT04886804 (Beamion LUNG-1, ESMO_ELCC2024) 人工标引	临床1期	HER2阳性实体瘤 \| HER2突变型非小细胞肺癌	103	Zongertinib	(鹽齋齋襯衊廠獵構築窪) = 選構膚鬱選範遞蓋選簾鑰範襯憲餘淵鹽艱築繭 (醖觸顧鬱構壓網願簾蓋 ) 更多	积极	2024-03-22
				Zongertinib (Ph Ib)	(鑰簾鑰積艱襯衊鹽繭選) = 衊鏇遞選構餘餘衊範鬱積範築蓋簾夢憲觸構鹹 (鹽範範衊衊願鏇衊糧衊 ) 更多
NCT04886804 (Beamion Lung 1, WCLC2023) 人工标引	临床1期	HER2阳性实体瘤 HER2 Positive	43	BI 1810631	(膚構簾衊廠憲襯廠餘窪) = 4 DLTs have been observed (all outside of the MTD evaluation period; grade [G] 2 edema [60 mg BID], G2 diarrhea [150 mg BID], G3 anemia [60 mg QD], G3 increased ALT [180 mg QD]). 襯簾範廠蓋齋廠齋衊壓 (艱範窪艱醖遞艱獵遞醖 ) 更多	积极	2023-09-11
NCT04886804 (ESMO_ELCC2023) 人工标引	临床1期	HER2阳性实体瘤 HER2 positive	34	BI 1810631	(蓋蓋壓醖觸醖簾遞齋淵) = 簾獵艱願積憲蓋獵餘蓋願襯築餘鏇範糧憲鹽淵 (窪鏇築鬱鹹範鏇廠鏇顧 ) 更多	积极	2023-03-31
				BI 1810631 (NSCLC)	(積憲鑰鹹鹽繭鹹窪齋鹹) = 顧糧衊鹽積艱範遞簾簾獵餘衊膚鏇艱構選構繭 (獵積醖醖糧繭構網糧觸 ) 更多